iPSC-EVs

Phase 1Biologic

HHuaqiu Zhang

iPSC-EVs is one of 5 biologic programs targeting Moyamoya disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Moyamoya DiseaseActive, not recruiting

Moyamoya DiseasePhase 1

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Moyamoya Disease

#DrugCompanyPhaseTrials

DL-3-N-Butylphthalide

FFirst Affiliated Hospital Xi'an Jiaotong University

Phase 3

1 2

Bayer Aspirin

Bayer

Preclinical

1 3

Sufenta

LLeaf Vertical Inc.

Preclinical

1 4

iPSC-EVs

HHuaqiu Zhang

Phase 1

1 5

Revascularization/conservative Management

MMinia University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Moyamoya Disease

NCT07065409

Clinical

Trials by Indication[1]

Moyamoya disease1 trial

Treatment of Moyamoya Disease With iPSC-derived Exosomes

Recruiting·HHuaqiu Zhang·Phase 1·NCT07065409·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for iPSC-EVs. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — iPSC-EVs compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for iPSC-EVs. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Huaqiu Zhang company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: HHuaqiu Zhang

iPSC-EVs

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Moyamoya disease1 trial

References

Drug Info

Quick Facts

Related News